Risk of Endometrial Cancer and Frequencies of Invasive Endometrial Procedures in Young Breast Cancer Survivors Treated With Tamoxifen: A Nationwide Study

被引:11
|
作者
Choi, Soojeong [1 ]
Lee, Young Jae [2 ]
Jeong, Jae Ho [3 ]
Jung, Jinhong [4 ]
Lee, Jong Won [1 ]
Kim, Hee Jeong [1 ]
Ko, Beom Seok [1 ]
Son, Byung Ho [1 ]
Ahn, Sei Hyun [1 ]
Lee, Yura [1 ,5 ]
Chung, Il Yong [1 ]
机构
[1] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul, South Korea
[2] Univ Ulsan, Coll Med, Gangneung Asan Hosp, Dept Obstet & Gynecol, Kangnung, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[4] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Med Informat, Seoul, South Korea
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
breast neoplasms; dilatation and curettage; gynecological examination; tamoxifen; endometrial neoplasms; SURGICAL ADJUVANT BREAST; ENDOCRINE THERAPY; LONG-TERM; WOMEN; PREVENTION; SOCIETY;
D O I
10.3389/fonc.2021.636378
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Although the guidelines recommend gynecological assessment and close monitoring for symptoms of endometrial cancer in postmenopausal breast cancer survivors taking tamoxifen (TAM), the risk of endometrial cancer in young breast cancer survivors has not yet been fully assessed. This study aimed to investigate the risk of developing endometrial cancer and the frequencies of gynecological examinations in young breast cancer survivors taking TAM in South Korea. Methods A nationwide retrospective cohort study was conducted using the Health Insurance Review and Assessment Service claims data. Kaplan-Meier analyses and log-rank tests were used to assess the probability of endometrial cancer, benign endometrial conditions, and the probability of invasive endometrial procedure. To analyze the risk of endometrial cancer and benign endometrial conditions, we used a multivariable Cox proportional hazards regression model. Results Between 2010 and 2015, 60,545 newly diagnosed female breast cancer survivors were included. The total person-years were 256,099 and 140 (0.23%) patients developed endometrial cancer during the study period. In breast cancer survivors aged >= 60 years [hazard ratio (HR), 5.037; 95% confidence interval (CI), 2.185-11.613], 50-59 years (HR, 4.343; 95% CI, 2.122-8.891), and 40-49 years (HR, 2.121; 95% CI, 1.068-4.213), TAM was associated with an increased risk of endometrial cancer. In subjects aged below 40 years, TAM did not significantly increase the risk of endometrial cancer. However, among the TAM subgroups, breast cancer survivors aged below 40 years [1.61 per 1,000 person-years (PY); HR, 12.460; 95% CI, 2.698-57.522] and aged 40-49 years (2.22 per 1,000 PY; HR, 9.667; 95% CI, 4.966-18.819) with TAM-related endometrial diseases showed significantly increased risks of endometrial cancer. Among the TAM subgroup with benign endometrial conditions, the ratios of the frequency of invasive diagnostic procedures to the incidence of endometrial cancer were higher in subjects under 40 than subjects aged 60 or more. Conclusion Young breast cancer survivors with TAM-related benign endometrial diseases are at a higher risk of developing endometrial cancer. Gynecological surveillance should be tailored to the risk of endometrial cancer in young breast cancer survivors to improve the early detection of endometrial cancer and avoid unnecessary invasive procedures.
引用
收藏
页数:9
相关论文
共 50 条
  • [22] Breast cancer susceptibility polymorphisms and endometrial cancer risk: a Collaborative Endometrial Cancer Study
    Healey, Catherine S.
    Ahmed, Shahana
    O'Mara, Tracy A.
    Ferguson, Kaltin
    Lambrechts, Diether
    Garcia-Dios, Diego A.
    Vergote, Ignace
    Amant, Frederic
    Howarth, Kimberley
    Gorman, Maggie
    Hodgson, Shirley
    Tomlinson, Ian
    Yang, Hannah P.
    Lissowska, Jolanta
    Brinton, Louise A.
    Chanock, Stephen
    Garcia-Closas, Montserrat
    Hall, Per
    Liu, Jianjun
    Shah, Mitul
    Pharoah, Paul D. P.
    Thompson, Deborah J.
    Rebbeck, Timothy R.
    Strom, Brian L.
    Dunning, Alison M.
    Easton, Douglas F.
    Spurdle, Amanda B.
    CARCINOGENESIS, 2011, 32 (12) : 1862 - 1866
  • [23] A RETROSPECTIVE STUDY OF TAMOXIFEN AND ENDOMETRIAL CANCER IN BREAST-CANCER PATIENTS
    ROBINSON, DC
    BLOSS, JD
    SCHIANO, MA
    GYNECOLOGIC ONCOLOGY, 1995, 59 (02) : 186 - 190
  • [24] TAMOXIFEN FOR BREAST-CANCER - ASSOCIATED ENDOMETRIAL CANCER
    GUSBERG, SB
    CANCER, 1990, 65 (07) : 1463 - 1464
  • [25] Endometrial cancer after breast cancer and relationship with tamoxifen
    Brugier, C.
    Fourchotte, V.
    Asselain, B.
    Plancher, C.
    De La Rochfordiere, A.
    Cottu, P.
    Petrow, P.
    Alran, S.
    Sastre, X.
    Salmon, R. J.
    EJC SUPPLEMENTS, 2010, 8 (03): : 67 - 67
  • [26] The effect of tamoxifen on the risk and prognosis of endometrial cancer following breast cancer.
    van Leeuwen, FE
    Bergman, L
    Beelen, MLR
    Gallee, MPW
    Benraadt, J
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 1998, 147 (11) : S64 - S64
  • [27] THE EVALUATION OF THE ENDOMETRIAL THICKNESS OF AMENHORREA BREAST CANCER PATIENTS TREATED WITH TAMOXIFEN
    Ayati, S.
    Yousefi, Z.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1014 - 1014
  • [28] Endometrial Surveillance Outcomes for a Cohort of Breast Cancer Patients Treated with Tamoxifen
    McLemore, M. S.
    Malpica, A.
    LABORATORY INVESTIGATION, 2010, 90 : 255A - 255A
  • [29] ENDOMETRIAL CHANGES IN POSTMENOPAUSAL WOMEN TREATED WITH TAMOXIFEN FOR BREAST-CANCER
    COHEN, I
    ROSEN, DJD
    SHAPIRA, J
    CORDOBA, M
    GILBOA, S
    ALTARAS, MM
    YIGAEL, D
    BEYTH, Y
    BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 1993, 100 (06): : 567 - 570
  • [30] Endometrial Cytologic Findings In Tamoxifen-Treated Breast Cancer Patients
    Hachisuga, Toru
    Emoto, Makoto
    Kawarabayashi, Tatsuhiko
    Kamihana, Yutaka
    Nabeshima, Kazuki
    ACTA CYTOLOGICA, 2009, 53 (01) : 24 - 28